Related resources
Full-text held externally
- PMID: 19370737
- UKPMCID: 19370737
- DOI: 10.1002/mds.22495
Search for item elsewhere
University researcher(s)
Academic department(s)
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Leroi, Iracema; Overshott, Ross; Byrne, E Jane; Daniel, Emily; Burns, Alistair
Movement disorders : official journal of the Movement Disorder Society. 2009;24(8):1217-21.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 19370737
- UKPMCID: 19370737
- DOI: 10.1002/mds.22495
Abstract
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD.